Extended Data Fig. 1: Validation of MALDI glycogen imaging with anti-glycogen antibody staining in lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) tissues.
From: Glycogen drives tumour initiation and progression in lung adenocarcinoma
a, Representative images of MALDI glycogen imaging (left) and corresponding anti-glycogen antibody staining (right) in two LUAD and one LUSC patient tissue samples. b, Detailed view of various tumor regions stained with anti-glycogen antibody showing predominately tumors positive for glycogen similar to MALDI analysis. Labels indicate tumor (T), stroma (S), normal adjacent tissue (N), vessels (V), necrosis (Ne), smooth muscle (SM), cartilage (C), and chondrocytes (Cc). c, Tissue overlays combining anti-glycogen antibody staining and MALDI glycogen imaging performed in SCILs software. The upper panels show the antibody staining with outlined regions for zoomed-in views, and the lower panels display the corresponding MALDI imaging overlays. c and c represent three biological replicates (individual patients). Black boxes indicate areas magnified in the zoomed-in images to illustrate the concordance between glycogen imaging and antibody staining.
